tbuckley/cabot-search huggingface dataset:
The effect of preoperative chemotherapy on lymph node yield in gastric cancer.
Authors: J. L. Dikken, P. Krijnen, C. J. Van De Velde, M. Verheij, M. Gonen, N. C. van Grieken, L. H. Tang, M. F. Brennan, D. G. Coit
Journal: Journal of Clinical Oncology (2011)

80 Background: While a minimum of 15 lymphnodes (LNs) should be evaluated for accurate staging of gastric cancer, LN yield in western countries is generally low. With the increasing use of preoperative chemotherapy, it is unknown what the effect of this treatment is on lymph node yield. The aim of the study is therefore to determine whether preoperative chemotherapy influences the number of LNs that can be obtained from specimens of patients who underwent curative surgery for gastric adenocarcinoma. Methods: In1,205 patients from a high-volume U.S. center and 1,220 patients from the Netherlands Cancer Registry (NCR) who underwent a total or distal gastrectomy with curative intent for gastric adenocarcinoma, the LN yield was compared between patients who received preoperative chemotherapy and patients who received no neoadjuvant therapy. Multivariate Poisson regression was used to identify significant predictors of LN retrieval. Results: Of the 2,425 patients who underwent a gastrectomy, 340 patients (14%) received preoperative chemotherapy. Median LN yields were 23 in the U.S. institution and 10 in the NCR. Separate multivariate analyses of the U.S. institution data and the NCR population showed in both groups that preoperative chemotherapy was not associated with a significant difference in LN yield (Table). Factors that were associated with higher LN yield were the same in both groups: female sex, younger age (6% more nodes with every 10 years decrease in age), total gastrectomy (vs. distal gastrectomy) and increasing tumor (T) stage. Conclusions: In both a high-volume cancer center, and a population-based cancer registry, female sex, younger age, total gastrectomy and advanced tumor stage were associated with an increase in lymph node retrieval in surgical specimens. Preoperative chemotherapy did not influence lymph node yield after a resection for gastric cancer. The threshold for what should constitute an adequate assessment of regional lymph nodes after curative surgery for gastric cancer should not be changed after administration of preoperative chemotherapy. [Table: see text] No significant financial relationships to disclose.
ANGI-07. THE EXPRESSION OF TOLL-LIKE RECEPTORS 2 AND CLINICAL SIGNIFICANCE IN HUMAN GLIOMAS
Authors: Yanli Tan, Mengmeng Yao, Chuan Fang
Journal: Neuro-Oncology (2016)

To investigate the expression of toll-like receptors 2 and discuss the significance of TLR2 in the development of human gliomas. The expression of TLR2 and CyclinD1, Ki67 were studied with immunohistochemical staining. 72 cases of paraffin embedded specimens of glioma tissues in our Hospital January 2014 to January 2016 were selected, including 35 males and 37 females, aged from 22 to 80 years old, with an average age of 51.4. According to the criteria of WHO 2007 central nervous system tumor classification: there were 49 cases of astrocytoma, 8 cases of oligodendroglioma and 15 cases of glioblastomas. Pathological grades: there were 3 cases in I grade, 36 cases in II grade, 18 cases in III grade and 15 cases in IV grade. The control group was 8 cases of normal brain tissues in patients with brain injury. Immunohistochemical results showed that the positive expressions of TLR2 was 64.71 %%, the expressions of it in the lower grade group (I, II) and the high grade group (III, IV) were statistically significant (X2=24.01, P<0.01). The expression of TLR2 was positively correlated with pathological grade of brain glioma (R =0.46, P<0.01). The positive expressions of Ki-67 and CyclinD1 in 72 cases of brain glioma were 60.78% and 64.71%, respectively. None of them expressed in normal brain tissues. In addition, TLR2 was positively correlated with the expression of CyclinD1 (R=0.75, P<0.01). The expression of TLR2 was positively correlated with Ki67 (R =0.983, P<0.05). The overexpression of TLR2 in human gliomas may play a crucial role in its pathologic grading and cell proliferation. It shows that TLR2 plays an important role in the development of human gliomas.
281 small cell bladder cancer analysis from spanish institutions
Authors: M.J. Juan Fita, M. Ramirez-Backhaus, X. Bonet Puntí, J. Gomez, E. Ramos, L. Pesquera, A. Rodriguez-Vida, I. Lacasa Viscasillas, J.C. Villa Guzman, R. Sanchez-Salas, J.L. Sanchez Sanchez, M.J. Miranda, S. Valverde, L. Izquierdo, A. Serrano, P. Pellejero, I. Garcia, I. Ortiz, J. Rubio Briones, M.A. Climent
Journal: Annals of Oncology (2016)
Deletion of Two Contiguous Genes, Platelet GPIbβ (Glycoprotein Ibβ) and Septin SEPT5, in a Boy with Bernard-Soulier Syndrome and Developmental Delay: A Possible New Contiguous Gene Syndrome.
Authors: Ingrid Bartsch, Ina Hainmann, Susanne Bläser, Anna Pavlova, Johannes Oldenburg, Anja Busse, Francois Lanza, Paquita Nurden, Andrea Superti-Furga, Barbara Zieger
Journal: Blood (2006)
Chemotherapy and Hair Loss
Authors: Christopher C. Muth
Journal: JAMA (2017)

Julie Nangia, MD; Tao Wang, PhD; Cynthia Osborne, MD; Polly Niravath, MD; Kristen Otte, BA; Steven Papish, MD; Frankie Holmes, MD; Jame Abraham, MD; Mario Lacouture, MD; Jay Courtright, MD; Richard Paxman, BSc; Mari Rude, ANP; Susan Hilsenbeck, PhD; C. Kent Osborne, MD; Mothaffar Rimawi, MD
Evaluation of stool chart for management of diarrhea induced by afatinib therapy
Authors: Rieko Nakamura, Nozomi Uehara, Naoko Otsuki, Rieko Sanuki, Kayoko Morisaka, Tetsuya Yoshida, Utae Katsusima, Asuka Tsuya, Haruko Daga, Koji Takeda
Journal: Annals of Oncology (2016)
Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial
Authors: Mahamadou S Sissoko, Sara A Healy, Abdoulaye Katile, Freda Omaswa, Irfan Zaidi, Erin E Gabriel, Bourama Kamate, Yacouba Samake, Merepen A Guindo, Amagana Dolo, Amadou Niangaly, Karamoko Niaré, Amatigue Zeguime, Kourane Sissoko, Hama Diallo, Ismaila Thera, Kelly Ding, Michael P Fay, Elise M O'Connell, Thomas B Nutman, Sharon Wong-Madden, Tooba Murshedkar, Adam J Ruben, Minglin Li, Yonas Abebe, Anita Manoj, Anusha Gunasekera, Sumana Chakravarty, B Kim Lee Sim, Peter F Billingsley, Eric R James, Michael Walther, Thomas L Richie, Stephen L Hoffman, Ogobara Doumbo, Patrick E Duffy
Journal: The Lancet Infectious Diseases (2017)
Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML
Authors: Stephen G O'Brien, Corinne Hedgley, Sarah Adams, Letizia Foroni, Jane F. Apperley, Tessa L Holyoake, Christopher Pocock, Jenny L Byrne, Lynn Margaret Seeley, Wendy L Osborne, John M Goldman, Mhairi Copland, Richard E Clark
Journal: Blood (2014)
Acetaminophen in Pregnancy and Adverse Childhood Neurodevelopment
Authors: David J. Beale
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia
Authors: Irene Ghobrial, Tiffany Poon, Meghan Rourke, Stacey Chuma, Janet Kunsman, Ranjit Banwait, Amy Sam, Diane Warren, Kenneth C. Anderson, Paul Richardson, Steven P. Treon, Jeffrey Matous
Journal: Blood (2010)
Influence of Age at Diagnosis On Utility of Prognostic Testing in Patients with CLL.
Authors: Tait D. Shanafelt, Kari Rabe, Neil E. Kay, Clive S. Zent, Diane F. Jelinek, Susan Schwager, Deborah Bowen, Susan L Slager, Megan Reinalda, Curtis A. Hanson, Timothy G Call
Journal: Blood (2009)
GENT-11. SMALL MOLECULE EPIGENETIC SCREEN IDENTIFIES NOVEL EZH2 AND HDAC INHIBITORS THAT TARGET GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS
Authors: Natalie Grinshtein, Constanza Rioseco, Richard Marcellus, David Uehling, Ahmed Aman, Xueqing Lun, Osamu Muto, Lauren Podmore, Gregory Cairncross, Steve Robbins, Steve Jones, Marco Marra, Rima Al-awar, Donna Senger, David Kaplan
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is the most lethal and aggressive adult brain tumor, requiring the development of efficacious therapeutics. Towards this goal, we screened five genetically distinct patient-derived brain-tumor initiating cell lines (BTIC) with a unique collection of small molecule epigenetic modulators from the Structural Genomics Consortium (SGC). We identified multiple hits that inhibited the growth of BTICs in vitro, and further evaluated the therapeutic potential of EZH2 and HDAC inhibitors due to the high relevance of these targets for GBM. We found that the novel SAM-competitive EZH2 inhibitor UNC1999 exhibited low micromolar cytotoxicity in vitro on a diverse collection of BTIC lines, synergized with dexamethasone (DEX) and suppressed tumor growth in vivo in combination with DEX. In addition, a unique brain-penetrant class I HDAC inhibitor exhibited cytotoxicity in vitro on a panel of BTIC lines and extended survival in combination with TMZ in an orthotopic BTIC model in vivo. Finally, we showed that a combination of EZH2 and HDAC inhibitors demonstrated synergy in vitro by augmenting apoptosis and increasing DNA damage. Our findings identify key epigenetic modulators in GBM that regulate BTIC growth and survival and highlight promising combination therapies.
P01.05 Differential expression patterns of the transforming growth factor (TGF)-beta receptors (TGF-bR) I ALK-1 and ALK-5 and TGF-bR II in glioblastoma
Authors: I. Burghardt, S. Krishnan
Journal: Neuro-Oncology (2016)

AbstractGlioblastomas use pro-angiogenic factors such as vascular endothelial growth factor (VEGF) for new blood vessel formation. Glioma-associated endothelial cells may support glioblastoma growth and specifically maintain glioma stem cells (GSC). Yet, anti-VEGF therapy does not prolong overall survival: gliomas acquire resistance to VEGF inhibition and appear to be rather refractory to all further treatments. Thus, investigations of alternative angiogenic pathways in gliomas which may then serve as essential drug targets are pivotal. Activin receptor-like kinases (ALK) are type I TGF-beta receptors (TGF-bR). Nonoverlapping expression patterns of ALK-1 and ALK-5 have been demonstrated with primarily endothelial expression of ALK-1. Both GSC and glioma-associated endothelial cells produce TGF-beta superfamily ligands which may sustain glioma self-renewal and promote immunosuppression in the tumor microenvironment. This is mediated by TGF-bR, specifically type I TGF-bR and type II TGF-bR, forming heteromeric complexes upon binding of TGF-bR superfamily ligands. We demonstrate an enrichment of ALK-1 and TGF-bR II in GSC and glioma-associated endothelial cells in a cohort of newly diagnosed and recurrent glioblastomas. This may define ALK-1 and TGF-bR II as promising future therapeutic targets in antiangiogenic therapy for glioblastoma.
Loss of Heterozygosity of Chromosome 1p34 and High Mutant Allele Burden in Patients with Post-Essential Thrombocythemia Myelofibrosis Carrying Somatic Mutations of MPL
Authors: Daniela Pietra, Elisa Rumi, Angela Brisci, Francesco Passamonti, Sabrina Boggi, Laura Cremonesi, Mario Lazzarino, Mario Cazzola
Journal: Blood (2008)
Dynamic contrast-enhanced MR imaging can distinguish between active and inactive multiple myeloma
Authors: Atsushi Isoda, Hisayoshi Mizunuma, Yoshitaka Tomaru, Tetsuya Ishikawa, Yuri Miyazawa, Momoko Mawatari, Morio Matsumoto, Morio Sawamura, Masana Matsuura, Masuo Ujita
Journal: Annals of Oncology (2016)
Chronic intermittent hypoxia mimicking sleep apnoea increases spontaneous tumorigenesis in mice
Authors: Teresa Gallego-Martin, Ramón Farré, Isaac Almendros, Elvira Gonzalez-Obeso, Ana Obeso
Journal: European Respiratory Journal (2017)

Obstructive sleep apnoea (OSA) is a very prevalent disorder with well proven mid- and long-term deleterious consequences, such as increased risk of cardiovascular, metabolic and neurocognitive diseases [1]. Recently, considerable data from both animal models and patient studies also suggest that OSA increases the risk of cancer incidence and mortality [2]. Some of these studies indicate that nocturnal hypoxic events experienced by OSA patients as a consequence of recurrent upper airway obstructions may be a main challenge driving tumour progression [3, 4]. Although the clinical and experimental data available do not undoubtedly prove a relationship between cancer and OSA [5], its plausibility has raised the interest of basic and clinical researchers in the field, warranting further investigation [6]. Chronic intermittent hypoxia mimicking sleep apnoea increases spontaneous tumorigenesis in mice <http://ow.ly/BoF6306AnI0> The authors thank Ana Gordillo (Universidad de Valladolid/CIBERES, Valladolid, Spain) for her technical support.
The Analysis of Mutual Relationship Between Hemostasis and Inflammatory Processes in Patients with Chronic Liver Diseases
Authors: Nora E. El-Bassiouni, Rania M. Benyamin, Samia H. Risk, Manal Y. Zahran, Ola M. Mahmoud, Raafat A. Ibrahim, Azza E. El Bassiouny
Journal: Blood (2015)
Recombinant granulocyte colony-stimulating factors (rG-CSFs) in the management of NEUtropenia induced by anthracyclines and ifosfamide in patients with soft tissue SARcomas (NEUSAR)
Authors: A. Bongiovanni, M. Monti, F. Foca, F. Recine, N. Riva, V. Di Iorio, C. Liverani, D.V. Alessandro, G. Miserocchi, L. Mercatali, G. Marcantognini, V. Fausti, S. Calpona, D. Amadori, T. Ibrahim
Journal: Annals of Oncology (2016)
SURG-37. MODERN POSTOPERATIVE SEIZURE PROPHYLAXIS WITH LEVETIRACETAM IN OVER 300 NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS
Authors: Arman Jahangiri, Patrick M. Flanigan, Sarah Choi, Alvin Chou, Maxine Arnush, Joshua Bruhn, Ruby Kuang, Albert Truong, Jennifer Clarke, Edward Chang, Michael McDermott, Susan Chang, Mitchel S. Berger, Manish Aghi
Journal: Neuro-Oncology (2016)

Seizures after glioblastoma surgery have been studied in small cohorts before the use of levetiracetam. We studied postoperative seizure rates temporally in a large modern cohort operated on since widespread levetiracetam availability in 2008. Retrospective review of 333 glioblastoma patients with initial craniotomy for glioblastoma at our institution 2008-2014. Mean age was 59.6 (range=21-88) with 207 (62%) male. Mean tumor diameter was 3.8 cm. GTR was achieved in 128/333 (38%) patients. 119/333 (34%) patients presented with seizure, receiving levetiracetam preoperatively. Of 214 (64%) remaining patients, 169 (79%) received prophylactic postoperative levetiracetam at the neurosurgeon’s discretion. Of 119 patients with preoperative seizures, 21 (18%) experienced postoperative seizure while on levetiracetam. Postoperatively, 11 patients (52%) seized during week one, 4 (19%) during week two, and weeks 3-13 plateaued to one seizure per week amongst the 119 patients. Only 2/45 (4%) patients not given postoperative levetiracetam prophylaxis had seizures. Of 169 patients without preoperative seizures given prophylactic levetiracetam at the neurosurgeon’s discretion, 13 (8%) seized on treatment. Similar to the patients with preoperative seizures, of those without preoperative seizures on postoperative prophylaxis, 9 (69%) patients had seizures during week 1, while weeks 2-13 had <1 seizure per week amongst the 169 patients. Our large retrospective study of modern seizure prophylaxis with levetiracetam revealed the initial post-operative week to be the most common seizure period regardless of pre-operative seizure status, emphasizing the timeframe during which patients without seizures should be prophylaxed and suggesting consideration for a second agent during this period in patients with preoperative seizures. Furthermore, the neurosurgeon’s discretion to choose which patients without preoperative seizures to give prophylactic levetiracetam to may select high risk patients, the variables of which we will seek to define, shedding light on the difficulty of randomized trials studying levetiracetam prophylaxis.
Gene Expression Profile Associated with Survival in Patients with Diffuse Large B-Cell Lymphoma Treated by Chemotherapy and Rituximab.
Authors: Karen Leroy, Jean-Philippe Jais, Corinne Haioun, David Rickman, Aurelien de Reynies, Thierry Molina, Bertrand Coiffier, Francoise Berger, Christian Gisselbrecht, Josette Briere, Felix Reyes, Philippe Gaulard, Pierre Feugier, Eric Labouyrie, Herve Tilly, Fabrice Jardin, Christian Bastard, Gilles Salles
Journal: Blood (2005)
Combining complementary mechanisms of immune activation: NKTR-214, a biased IL-2 pathway agonist and immune checkpoint antagonists
Authors: D.H. Charych, P. Kuo, M. Addepalli, V. Dixit, R. Pena, W. Rubas, U. Hoch, J. Langowski, S.K. Doberstein, J. Zalevsky
Journal: Annals of Oncology (2016)
Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome
Authors: Haesook T Kim, Philippe Armand, David Frederick, Emily Andler, Corey S Cutler, John Koreth, Edwin P. Alyea, Joseph H. Antin, Robert J Soiffer, Jerome Ritz, Vincent T. Ho
Journal: Blood (2014)
The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer
Authors: Min-Wei Chen, Shu-Ting Yang, Ming-Hsien Chien, Kuo-Tai Hua, Chin-Jui Wu, S.M. Hsiao, Hao Lin, Michael Hsiao, Jen-Liang Su, Lin-Hung Wei
Journal: Cancer Research (2017)

Ovarian cancer spheroids constitute a metastatic niche for transcoelomic spread that also engenders drug resistance. Spheroid-forming cells express active STAT3 signaling and display stem cell-like properties that may contribute to ovarian tumor progression. In this study, we show that STAT3 is hyperactivated in ovarian cancer spheroids and that STAT3 disruption in this setting is sufficient to relieve chemoresistance. In an NSG murine model of human ovarian cancer, STAT3 signaling regulated spheroid formation and self-renewal properties, whereas STAT3 attenuation reduced tumorigenicity. Mechanistic investigations revealed that Wnt signaling was required for STAT3-mediated spheroid formation. Notably, the Wnt antagonist DKK1 was the most strikingly upregulated gene in response to STAT3 attenuation in ovarian cancer cells. STAT3 signaling maintained stemness and interconnected Wnt/β-catenin signaling via the miR-92a/DKK1-regulatory pathways. Targeting STAT3 in combination with paclitaxel synergistically reduced peritoneal seeding and prolonged survival in a murine model of intraperitoneal ovarian cancer. Overall, our findings define a STAT3-miR-92a-DKK1 pathway in the generation of cancer stem-like cells in ovarian tumors, with potential therapeutic applications in blocking their progression. Cancer Res; 77(8); 1955-67. ©2017 AACR.
Development of a nationwide genomic screening project (LC-SCRUM-Japan) for small cell lung cancer for precision medicine
Authors: Masahiro Shinoda, Shigeki Umemura, Shoichi Kuyama, Satoshi Hara, Masato Shingyoji, Takeshi Tsuda, Toshiyuki Harada, Tetsuhiro Shiota, Shingo Matsumoto, Koichi Goto
Journal: Annals of Oncology (2016)
Structural Basis and Cellular Consequences of Potent Inhibition of the Aurora Kinases, Wild Type Abl Kinase and a T315I Multi-Drug Resistant Mutant Form of Abl Kinase by MK-0457 (VX-680).
Authors: John R. Pollard, Peter A. Charlton, Graham M.T. Cheetham, Susanna C. Falcon, Julian M.C. Golec, Matthew R. Griffiths, Peter Weber
Journal: Blood (2006)
NIMG-29. TUMOR RECURRENCE IN AREAS OF LOWER TTFIELDS INTENSITY: A REVERSE SIMULATION CASE STUDY
Authors: James Battiste, Michael Sughrue, Ariel Naveh, Aafia Chaudhry
Journal: Neuro-Oncology (2016)

Anecdotal evidence suggests glioblastoma can recur in areas of lower TTFields intensity. A 43-year old female with heavily pre-treated, recurrent high grade glioma underwent treatment planning for TTFields. Therapy was planned to the boundaries of a temporal resection cavity margin using the NovoTAL System. Prior to TTFields therapy, the patient required skull flap removal due to infection. As TTFields transducer arrays cannot be placed over skull defects, the array placement on the scalp significantly deviated from the planned NovoTAL transducer array layout. At 3 months, the patient experienced progressive disease at the resection cavity margin. In order to test whether the recurrence in this patient occurred in a region of low intensity, an EF simulation was performed using a rescaled realistic anatomic head model, into which both the bone flap and resection cavity were inserted. MRI data guided contouring of the resection cavity margin, craniectomy, delineation of a region of peritumoral brain (PBZ) as the site of recurrence, and model arrays were placed in a deviated configuration on the scalp to mimic clinical delivery. The model was meshed and solved using the Sim4Life software package, and TTFields intensity in the region of recurrence was determined. The simulation demonstrated that the percentage of PBZ (recurrence area) receiving TTFields >2V/cm was only 37% and 10% in the L-R and A-P directions respectively. However, as TTFields cannot be delivered in a focal manner, the field intensity in immediate adjacent regions was largely similar. Our evaluation of the electric field intensity suggests that gliomas can recur in areas of lower median field intensity, and field optimization could improve outcomes. Therefore, further studies are warranted to characterize the recurrence patterns of high grade gliomas after TTFields therapy in order to improve the tumor responses.
Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis
Authors: Stephan Ehrmann, Andrew Quartin, Brian P Hobbs, Vincent Robert-Edan, Cynthia Cely, Cynthia Bell, Genevieve Lyons, Tai Pham, Roland Schein, Yimin Geng, Karim Lakhal, Chaan S. Ng
Journal: Intensive Care Medicine (2017)
Risk factors for brain metastases in patients with metastatic colorectal cancer
Authors: T.D. Christensen, J.A. Palshof, F.O. Larsen, E. Høgdall, T.S. Poulsen, B.V. Jensen, P. Pfeiffer, M.K. Yilmaz, I.J. Christensen, D.L. Nielsen
Journal: Annals of Oncology (2016)
Association between Genetic Polymorphisms of β-Cell Differentiation Genes and Insulin Resistance (β-Cell Dysfunction) in Childhood Acute Lymphoblastic Leukemia (ALL) Survivors.
Authors: Pacharapan Surapolchai, Suradej Hongeng, Samart Pakakasama, Pat Mahachoklertwattana, Angkana Winaichatsak, Nittaya Wisanuyothin, Wasun Chantratita, Nongnuch Sirachainan
Journal: Blood (2007)
Targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) cell lines - a potential prognostic biomarker in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1)
Authors: A. Stahler, S. Stintzing, M. Urbischek, D.P. Modest, L. Fischer von Weikersthal, J. Kumbrink, V. Heinemann, T. Kirchner, A. Jung
Journal: Annals of Oncology (2016)
Immune Gene Therapy for Patients with CLL Using Repeat Dose Intranodal Injection of Ad-ISF35, a Replication Incompetent Vector Expressing a Membrane-Stable CD40 Binding Protein.
Authors: Januario E Castro, Johanna Melo-Cardenas, Juan Sebastian Barajas-Gamboa, Ramin Sean Pakbaz, Mauricio Urquiza, Thomas J. Kipps
Journal: Blood (2010)